Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CKDB-326 is a probiotic-based therapeutic candidate being developed by CKDBiO (Chong Kun Dang Bio) for the treatment of chronic cholestatic liver diseases, including Primary Sclerosing Cholangitis (PSC) and Primary Biliary Cholangitis (PBC). As a live biotherapeutic product, CKDB-326 is designed to modulate the gut-liver axis, potentially addressing the underlying inflammation and bile acid dysregulation characteristic of these autoimmune biliary diseases. The drug is currently in the preclinical/discovery stage of development.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on CKDB-326.